Innovative therapies for better lives
Herantis focuses on disease modifying, CDNF-based therapies for Parkinson’s disease that aim to restore proteostasis, body’s natural neuronal protective mechanism. A failure in proteostasis results in pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated in the development of neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease. CDNF is a protein that occurs naturally in the body. Its role is to protect neurons by balancing proteostasis, thereby preventing and counteracting disease generating mechanisms.
Herantis molecules in development are CDNF-based; HER-096 (a synthetic peptide) and rhCDNF (a biological protein). HER-096 and rhCDNF have both demonstrated to have a multimodal mechanism of action mimicking CDNF and to improve functional recovery of damaged neurons in preclinical models. Importantly, HER-096 has been shown to readily penetrate the blood brain barrier allowing for convenient subcutaneous dosing. Thanks to their multimodal mechanism of action, Herantis’ molecules have the potential to stop the progression of Parkinson’s disease and significantly improve patients’ quality of life.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.